Literature DB >> 30306591

Cancer of the ovary, fallopian tube, and peritoneum.

Jonathan S Berek1, Sean T Kehoe2, Lalit Kumar3, Michael Friedlander4,5.   

Abstract

The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.
© 2018 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  Cancer staging; Chemotherapy; FIGO Cancer Report; Fallopian tube; Ovarian; Ovary; Peritoneum

Mesh:

Year:  2018        PMID: 30306591     DOI: 10.1002/ijgo.12614

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  63 in total

Review 1.  Multimodality imaging and genomics of granulosa cell tumors.

Authors:  Sherif Elsherif; Matthew Bourne; Erik Soule; Chandana Lall; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-03

2.  Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.

Authors:  Hasan Turan; Salvatore Giovanni Vitale; Ilker Kahramanoglu; Luigi Della Corte; Pierluigi Giampaolino; Asli Azemi; Sinem Durmus; Veysel Sal; Nedim Tokgozoglu; Tugan Bese; Macit Arvas; Fuat Demirkiran; Remise Gelisgen; Sennur Ilvan; Hafize Uzun
Journal:  Arch Gynecol Obstet       Date:  2022-04-24       Impact factor: 2.344

3.  CHALLENGES OF AN OVARIAN NEUROENDOCRINE METASTASIS OF ADVANCED SMALL-CELL LUNG CARCINOMA - LITERATURE REVIEW AND CASE REPORT.

Authors:  V N Varlas; G Angelescu; Y Rhazi; B A Năsui; A L Pop; M L Gheorghiu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

4.  STAT3 mediates RCP-induced cancer cell invasion through the NF-κB/Slug/MT1-MMP signaling cascade.

Authors:  Su Jin Cho; Bo Young Jeong; Young Soo Song; Chang Gyo Park; Do Yeun Cho; Hoi Young Lee
Journal:  Arch Pharm Res       Date:  2022-07-09       Impact factor: 6.010

5.  miRNA Expression in Ovarian Cancer in Fresh Frozen, Formalin-fixed Paraffin-embedded and Plasma Samples.

Authors:  Patrick H D Petersen; Joanna Lopacinska-Jørgensen; Douglas V N P Oliveira; Claus K Høgdall; Estrid V Høgdall
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

6.  Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin.

Authors:  Chikage Narui; Hiroshi Tanabe; Jason S Shapiro; Yoko Nagayoshi; Takenori Maruta; Momoko Inoue; Yukihiro Hirata; Hiromi Komazaki; Hirokuni Takano; Shigeki Niimi; Seiji Isonishi; Aikou Okamoto
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

7.  [Effect of stable overexpression of XAF1 gene on biological characteristics of ovarian cancer A2780 cells].

Authors:  J Liu; X Liu; B Wei; J Liu; Y Wang; H Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-05-20

8.  Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort.

Authors:  Zheng Feng; Hao Wen; Ruimin Li; Shuai Liu; Yi Fu; Xiaojun Chen; Rui Bi; Xingzhu Ju; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

Review 9.  Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer.

Authors:  Sonia Missiroli; Mariasole Perrone; Caterina Boncompagni; Chiara Borghi; Alberto Campagnaro; Francesco Marchetti; Gabriele Anania; Pantaleo Greco; Francesco Fiorica; Paolo Pinton; Carlotta Giorgi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 10.  Ovarian cancer staging: What the surgeon needs to know.

Authors:  Lucas Roberto Lelis Botelho de Oliveira; Natally Horvat; Pamela Ines Causa Andrieu; Pedro Sergio Brito Panizza; Giovanni Guido Cerri; Publio Cesar Cavalcante Viana
Journal:  Br J Radiol       Date:  2021-07-21       Impact factor: 3.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.